Unconventional T Cell Targets for Cancer Immunotherapy

Dale I. Godfrey, Jérôme Le Nours, Daniel M. Andrews, Adam P. Uldrich, Jamie Rossjohn

Research output: Contribution to journalReview ArticleResearchpeer-review

41 Citations (Scopus)

Abstract

Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility complex (MHC) class I and MHC class II molecules, respectively. However, unconventional T cells, which interact with MHC class Ib and MHC-I like molecules, are also implicated in tumor immunity, although their role therein is unclear. These include unconventional T cells targeting MHC class Ib molecules such as HLA-E and its murine ortholog Qa-1b, natural killer T (NKT) cells, mucosal associated invariant T (MAIT) cells, and γδ T cells. Here, we review the current understanding of the roles of these unconventional T cells in tumor immunity and discuss why further studies into the immunotherapeutic potential of these cells is warranted. Godfrey et al. review the current understanding of the roles of unconventional T cells in tumor immunity, and discuss the therapeutic potential of harnessing the anti-tumor functions of cells characterized by repeated patterns of TCR usage in unrelated individuals.

Original languageEnglish
Pages (from-to)453-473
Number of pages21
JournalImmunity
Volume48
Issue number3
DOIs
Publication statusPublished - 20 Mar 2018

Cite this

Godfrey, Dale I. ; Le Nours, Jérôme ; Andrews, Daniel M. ; Uldrich, Adam P. ; Rossjohn, Jamie. / Unconventional T Cell Targets for Cancer Immunotherapy. In: Immunity. 2018 ; Vol. 48, No. 3. pp. 453-473.
@article{f93f3f925d0645039c7a317364397bf2,
title = "Unconventional T Cell Targets for Cancer Immunotherapy",
abstract = "Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility complex (MHC) class I and MHC class II molecules, respectively. However, unconventional T cells, which interact with MHC class Ib and MHC-I like molecules, are also implicated in tumor immunity, although their role therein is unclear. These include unconventional T cells targeting MHC class Ib molecules such as HLA-E and its murine ortholog Qa-1b, natural killer T (NKT) cells, mucosal associated invariant T (MAIT) cells, and γδ T cells. Here, we review the current understanding of the roles of these unconventional T cells in tumor immunity and discuss why further studies into the immunotherapeutic potential of these cells is warranted. Godfrey et al. review the current understanding of the roles of unconventional T cells in tumor immunity, and discuss the therapeutic potential of harnessing the anti-tumor functions of cells characterized by repeated patterns of TCR usage in unrelated individuals.",
author = "Godfrey, {Dale I.} and {Le Nours}, J{\'e}r{\^o}me and Andrews, {Daniel M.} and Uldrich, {Adam P.} and Jamie Rossjohn",
year = "2018",
month = "3",
day = "20",
doi = "10.1016/j.immuni.2018.03.009",
language = "English",
volume = "48",
pages = "453--473",
journal = "Immunity",
issn = "1074-7613",
publisher = "Elsevier",
number = "3",

}

Unconventional T Cell Targets for Cancer Immunotherapy. / Godfrey, Dale I.; Le Nours, Jérôme; Andrews, Daniel M.; Uldrich, Adam P.; Rossjohn, Jamie.

In: Immunity, Vol. 48, No. 3, 20.03.2018, p. 453-473.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Unconventional T Cell Targets for Cancer Immunotherapy

AU - Godfrey, Dale I.

AU - Le Nours, Jérôme

AU - Andrews, Daniel M.

AU - Uldrich, Adam P.

AU - Rossjohn, Jamie

PY - 2018/3/20

Y1 - 2018/3/20

N2 - Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility complex (MHC) class I and MHC class II molecules, respectively. However, unconventional T cells, which interact with MHC class Ib and MHC-I like molecules, are also implicated in tumor immunity, although their role therein is unclear. These include unconventional T cells targeting MHC class Ib molecules such as HLA-E and its murine ortholog Qa-1b, natural killer T (NKT) cells, mucosal associated invariant T (MAIT) cells, and γδ T cells. Here, we review the current understanding of the roles of these unconventional T cells in tumor immunity and discuss why further studies into the immunotherapeutic potential of these cells is warranted. Godfrey et al. review the current understanding of the roles of unconventional T cells in tumor immunity, and discuss the therapeutic potential of harnessing the anti-tumor functions of cells characterized by repeated patterns of TCR usage in unrelated individuals.

AB - Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility complex (MHC) class I and MHC class II molecules, respectively. However, unconventional T cells, which interact with MHC class Ib and MHC-I like molecules, are also implicated in tumor immunity, although their role therein is unclear. These include unconventional T cells targeting MHC class Ib molecules such as HLA-E and its murine ortholog Qa-1b, natural killer T (NKT) cells, mucosal associated invariant T (MAIT) cells, and γδ T cells. Here, we review the current understanding of the roles of these unconventional T cells in tumor immunity and discuss why further studies into the immunotherapeutic potential of these cells is warranted. Godfrey et al. review the current understanding of the roles of unconventional T cells in tumor immunity, and discuss the therapeutic potential of harnessing the anti-tumor functions of cells characterized by repeated patterns of TCR usage in unrelated individuals.

UR - http://www.scopus.com/inward/record.url?scp=85043788474&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2018.03.009

DO - 10.1016/j.immuni.2018.03.009

M3 - Review Article

VL - 48

SP - 453

EP - 473

JO - Immunity

JF - Immunity

SN - 1074-7613

IS - 3

ER -